利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

210 条记录 (耗时 0.031 秒)

    KALLIKREIN INHIBITORS AND USES THEREOF
    81.
    发明公开
    KALLIKREIN INHIBITORS AND USES THEREOF 审中-公开
    KALLIKREIN抑制剂及其用途

    公开(公告)号：EP3202414A1

    公开(公告)日：2017-08-09

    申请号：EP16205563.6

    申请日：2005-09-22

    申请人： Dyax Corp.

    发明人： Ladner,, Robert C ,  Ley,, Arthur C ,  Hirani,, Shirish ,  Williams,, Anthony ,  De Simoni,, Maria Grazia ,  Bergamaschini,, Luigi ,  Blair,, Henry ,  Beck,, Thomas

    IPC分类号： A61K38/17 ,  A61K31/195 ,  A61K38/48 ,  A61K38/55 ,  A61K45/06

    CPC分类号： A61K38/55 ,  A61K31/195 ,  A61K38/57 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient by administering a kalliekrein inhibitor.

    摘要翻译： 描述了包括非天然存在的激肽释放酶抑制剂和抗血栓溶解剂（例如抗纤维蛋白溶解剂）的方法，试剂盒和组合物，用于预防或减少失血和/或缺血，例如与围手术期失血相关的局部缺血 和脑缺血，全身炎症反应的发作和/或再灌注损伤，例如与脑缺血或局灶性脑缺血相关的再灌注损伤，例如在经历侵入性外科手术的患者中，尤其是需要体外循环的手术。 描述了通过施用激肽释放酶抑制剂来预防或减少患者的局部缺血，例如脑缺血和/或再灌注损伤（例如与脑缺血相关的再灌注损伤）的方法。

    ANTI-PLASMA KALLIKREIN ANTIBODIES
    83.
    发明公开
    ANTI-PLASMA KALLIKREIN ANTIBODIES 审中-公开
    ANTI-PLASMAKALLIKREINANTIKÖRPER

    公开(公告)号：EP2970502A4

    公开(公告)日：2016-11-30

    申请号：EP14769643

    申请日：2014-03-14

    申请人： DYAX CORP

    发明人： NIXON ANDREW ,  KENNISTON JON A ,  COMEAU STEPHEN R

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    摘要： Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES
    87.
    发明公开
    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES 审中-公开
    抗体与磷酸胆碱（PC）和/或PC偶联物结合

    公开(公告)号：EP2741770A4

    公开(公告)日：2014-12-31

    申请号：EP12821512

    申请日：2012-08-08

    申请人： ATHERA BIOTECHNOLOGIES AB ,  DYAX CORP

    发明人： PETTERSSON KNUT ,  CAMBER OLA ,  SEXTON DAN ,  NIXON ANDREW E

    IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/18 ,  C07K16/44

    CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

    摘要： The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.

    摘要翻译： 本公开涉及能够结合磷酸胆碱和/或磷酸胆碱缀合物的抗体或抗体片段，其中所述抗体或抗体片段包含可变重链（VH）结构域和/或可变轻链（VL）结构域，以及 其中（a）VH结构域包含选自以下的互补决定区（CDR）：与SEQ ID NO：7的序列具有同一性的CDR1序列; 与SEQ ID NO：8的序列具有同一性的CDR2序列; 和与SEQ ID NO：9或10的序列具有同一性的CDR3序列; 和/或（b）VL结构域包含选自以下的CDR：与SEQ ID NO：11的序列具有同一性的CDR4序列; 与SEQ ID NO：12的序列具有同一性的CDR5序列; 与SEQ ID NO：13的序列具有同一性的CDR6序列。

    NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE
    90.
    发明公开
    NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE 审中-公开
    的新型抗体磷酸胆碱

    公开(公告)号：EP2742068A1

    公开(公告)日：2014-06-18

    申请号：EP12747915.2

    申请日：2012-08-08

    申请人： Athera Biotechnologies AB ,  Dyax Corp.

    发明人： PETTERSSON, Knut ,  CAMBER, Ola ,  SEXTON, Dan ,  NIXON, Andrew E

    IPC分类号： C07K16/44 ,  A61K39/395 ,  A61P37/06 ,  A61P9/10

    CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/92

    摘要： The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.